ChatGPT
Log in
You said:
Neftaly Guidelines for the routine investigation and monitoring of adult HIV-1-positive individuals
ChatGPT said:
Here’s an overview of current South African—and by extension regional—guidelines on routine investigation and monitoring of adult HIV‑1‑positive individuals. These reflect the recommendations issued by the Southern African HIV Clinicians Society and national Department of Health, with the latest update in June 2023 Sajhivmed+8Sahivsoc+8Sahivsoc+8.
???? Baseline (at HIV diagnosis or ART initiation)
- Confirm HIV diagnosis using two distinct tests, at least one being a lab-based method (e.g. rapid + ELISA, or include viral load) Sahivsoc.
- CD4⁺ count at baseline to assess immune status and guide prophylaxis decisions (e.g. if < 200 cells/µL, give cotrimoxazole and consider cryptococcal antigen screening) SahivsocPMC.
???? Viral Load Monitoring
- Perform a viral load (VL) at 6 months and 12 months after ART initiation, then annually if suppressed (< 50 copies/mL) Sahivsoc+4MyCpdZw+4Sahivsoc+4.
- A sustained VL target of < 50 copies/mL is preferred; virological failure threshold has been lowered from 1,000 to 50 copies/mL to prompt earlier intervention PMC.
???? CD4⁺ Monitoring (Ongoing)
- After baseline, routine CD4 monitoring is no longer recommended once the patient is clinically stable and CD4⁺ is > 200 cells/µL. CD4 remains useful only for OI risk stratification in selected cases (e.g. low baseline CD4 or unsuppressed VL) SahivsocPMC.
???? Clinical Monitoring and Stability Definition
- A patient is considered clinically stable if they have no active opportunistic infections, are ≥ 6 months on ART, and have VL < 1,000 copies/mL (or CD4 > 200 if VL unavailable) Sahivsoc+8MyCpdZw+8Sahivsoc+8.
- Stable patients should be seen for clinical review about every 6 months (e.g. adherence counseling, side effects, screening for new comorbidities) MyCpdZwSahivsoc.
???? ART Monitoring Schedule Summary
| Timepoint | Assessment/Investigations |
|---|---|
| Baseline (pre‑ART/initiation) | HIV confirmation (dual testing), CD4 count, basic screening (renal/liver etc.) |
| 6 months after ART start | Viral load, clinical review |
| 12 months after ART start | Viral load, clinical status assessment |
| Annual thereafter (if suppressed) | Annual VL, clinical review every 6 months |
| In case of elevated VL (> 50 copies/mL) | Intensify adherence support → repeat VL per policy → consider regimen switch if persistent failure |
???? Special Situations
- Pregnancy/breastfeeding: Pregnant women on ART get VL at first ANC visit and every 6 months during pregnancy and breastfeeding; newly diagnosed individuals should start ART immediately and have VL monitoring at 3 months post-initiation MyCpdZwSahivsoc.
- Tuberculosis co-infection: Additional monitoring and prophylaxis (e.g. IPT, steroids for IRIS) follow national TB/HIV integrated care modules PMCMyCpdZw.
- Virological failure or DTG-era failure: If emerging resistance suspected, resistance testing decisions should be guided by national criteria; routine genotyping is not universally required under DTG-based first-line ART regimens Sahivsoc+2Sahivsoc+2PMC+2.
✅ Key Take‑Away Points:
- VL is the primary tool to assess treatment success (targets < 50 copies/mL).
- CD4 counts only needed at baseline or if OI risk is present; otherwise, routine CD4 monitoring is not required.
- Once stable, adults on ART typically require less frequent visits—clinical check‑ins every 6 months, annual VL, and baseline labs only.
If you’d like full PDF versions of these guidelines (e.g. the full Module 15: Laboratory monitoring or Module 6: Baseline investigations), or want details about drug toxicities, renal/liver screening, resistance management, or monitoring during OIs or pregnancy, just let me know!
ChatGPT can make mistakes. Check important info. See Cookie Preferences.
Original text
Rate this translation
Your feedback will be used to help improve Google Translate